Table 2.
Site | TNM classification | Grade | Therapy | p16 status | p16 intensity | % of p16+ tumor cells | HPV status | Local failure | Distant failure | Follow-up |
---|---|---|---|---|---|---|---|---|---|---|
Maxillary sinus | T4N0M0 | Cribriform | S+RT | − | 2 | 30 | − | Yes | Yes | DOD |
Maxillary sinus | T4N0M0 | Cribriform | S+IORT+RT | + | 3 | 70 | − | Yes | Yes | M |
Maxillary sinus | T4N0M0 | Cribriform | S | − | 2 | 60 | − | No | Yes | DOD |
Maxillary sinus | T4N0M0 | Cribriform | S+RT | − | 3 | 20 | − | Yes | No | DOD |
Maxillary sinus | T4N0M0 | Solid | S+RT | − | 3 | 50 | − | No | No | NED |
Maxillary sinus | T4N0M0 | Cribriform | S+RT | − | 2 | 40 | − | Yes | Yes | DOD |
Maxillary sinus | T3N0M0 | Cribriform | S | − | 2 | 10 | − | Yes | Yes | DOD |
Maxillary sinus | T3N0M0 | Solid | S+IORT | − | 3 | 20 | − | No | Yes | DOD |
Maxillary sinus | T3N0M0 | Cribriform | S+RT | − | 2 | 30 | − | Yes | Yes | M |
Nasal cavity | T4N0M0 | Cribriform | S+RT | − | 2 | 50 | − | No | No | NED |
Nasal cavity | T4N0M0 | Solid | S+RT | − | 2 | 10 | − | Yes | Yes | DOD |
Nasal cavity | T3N0M0 | Cribriform | S+CRT | − | 3 | 50 | − | No | No | NED |
Nasal cavity | T3N0M0 | Cribriform | S+RT | − | 2 | 10 | − | No | No | NED |
Nasal cavity | T2N0M0 | Solid | S | + | 3 | 100 | + | Yes | Yes | DOD |
Nasal cavity | T1N0M0 | Cribriform | S | − | 3 | 60 | − | No | No | NED |
Sphenoid sinus | T4N0M0 | Cribriform | S+RT | − | 3 | 40 | − | No | Yes | DOD |
Ethmoid sinus | T3N0M0 | Tubular | S+RT | − | 3 | 50 | − | Yes | No | DOD |
Abbreviations: CRT=concurrent chemoradiation; DOD=dead of disease; IORT=intraoperative radiation therapy; M=metastatic disease; NED=no evidence of disease; RT=external beam radiation therapy; S=surgery